PipelineHuidaGene has multiple R&D pipelines for ophthalmology and neurology.
-
01Neurology Diseases
MECP2 Duplication Syndrome (MDS)
Huntington's Disease (HD)
Amyotrophic Lateral Sclerosis (ALS)
-
02Ophthalmology Diseases
RPE65 Mutation-Associated Inherited Retinal Dystrophies (RPE65-IRD)
Neovascular Age-related Macular Degeneration (nAMD)
RHO-Associated Retinitis Pigmentosa (RHO-adRP)
-
03Neuromuscular Diseases
-
HuidaGene Therapeutics Announced First Patient Dosed in the HERO Clinical Trial of HG204 for MECP2 Duplication SyndromeDec 06,2024
Learn More
-
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular DegenerationNov 04,2024
Learn More
-
HuidaGene Therapeutics to Attend BIO-Europe Fall 2024 to Expand Global Collaborations in Genome MedicinesOct 28,2024
Learn More